University of Minnesota
MICaB Graduate Program
http://micab.umn.edu
MICaB Home | U of M Medical School | Graduate School

Unit's home page.

MICaB Faculty

Moriarity
Branden Moriarity, Ph.D.

Assistant Professor

Department of Pediatrics

University of Minnesota, 2012, Ph.D.

612-625-2226 office
612-625-2226 lab

E-mail:mori0164@umn.edu


Research Interests:

Pediatric cancer genetics, Gene-editing, Immunotherapy

Pediatric cancer genetics, gene and immunotherapy, genome engineering. Dr. Moriarity’s laboratory is working on studying the genetics of pediatric cancer, including sarcomas and brain tumors, to identify novel therapeutic targets to better treat pediatric cancer patients. The Moriarity lab uses animal models and comparative genomics approaches to identify new candidate cancer genes. Once identified, candidate genes are functionally studied in human cancer and immortalized cell lines using cutting edge technologies, such as targeted nucleases. The primary targeted nucleases used in the Moriarity lab are the CRISPR/Cas9 and Transcriptional Activator-Like Effector (TALEN) systems, which are used to knockout genes, induce targeted sequence changes, activate and/or repress endogenous gene expression. 

Selected Recent Publications:

  • Natalie K. Wolf, David A. Largaespada, Branden S. Moriarity. 2015. Coping with cancer genes altered by copy number. Oncotarget. Nov 3;6(34):35155-6.
  • Amy P Chiu, Barbara R Tschida, Lilian H Lo, Branden S Moriarity, Dewi K Rowlands, David A Largaespada, Vincent W Keng. 2015. Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma. World J Gastroenterol. Nov 14;21(42):12157-70.
  • Nuri A. Temiz*, Branden S. Moriarity*, Natalie K. Wolf, David Largaespada, Aaron L. Sarver. 2016. Transposon-RNA fusion sequence from SB accelerated muring tumors allows precision analyses of forward genetic cancer screens. Genome Res. Jan;26(1):119-29. *These authors contributed equally
  • Lisa Mirabello*, Roelof Koster*, Branden Moriarity, Logan Spector, Paul S. Meltzer, Mitchell J. Machiela, Nathan Pankratz, Orestis Panagiotou, David Largaespada, Zhaoming Wang, Julie M. Gastier-Foster, Richard Gorlick, Chand Khanna, Silvia Regina Caminada de Toledo, Antonio S. Petrilli, Ana Patiño-Garcia, Luis Sierrasesúmaga, Fernando Lecanda, Irene L. Andrulis, Jay S. Wunder, Nalan Gokgoz, Massimo Serra, Claudia Hattinger, Piero Picci, Adrienne M. Flanagan, Roberto Tirabosco, Maria Fernanda Amary, Dina Halai, Mandy Ballinger, David M. Thomas, Donald A. Barkauskas, Neyssa Marina, Lee Helman, George M. Otto, Kelsie L. Becklin, Natalie K. Wolf, Madison T. Weg, Margaret Tucker, Sholom Wacholder, Joseph F. Fraumeni, Jr., Neil E. Caporaso, Joseph F. Boland, Belynda D. Hicks, Aurelie Vogt, Laurie Burdette, Meredith Yeager, Robert N. Hoover, Stephen J. Chanock, Sharon A. Savage. 2015. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov. 5(9):920-31. *Co-First Authors
  • Marc Zuckermann, Volker Hovestadt, Christiane B. Knobbe-Thomsen, Marc Zapatka, Paul A. Northcott, Kathrin Schramm, Jelena Belic, David T.W. Jones, Barbara Tschida, Branden Moriarity, David Largaespada, Martine F. Roussel, Andrey Korshunov, Guido Reifenberger, Stefan M. Pfister, Peter Lichter, Daisuke Kawauchi & Jan Gronych. 2015. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nature Communications. Jun 11; 6:7391.
  • Branden S. Moriarity and D.A. Largaespada. 2015. Sleeping Beauty Transposon Insertional Mutagenesis Based Mouse Models for Cancer Gene Discovery. Current Opinion in Genetics & Development. Jun 3; 30:66-72.
  • Branden S. Moriarity, George M. Otto, Natalie Wolf, Luke A. Manlove, Eric P. Rahrmann, Sam Molyneux, Kevin Holly, Aaron L. Sarver, Chand Khanna, Stephen Hewitt, Marc lydania, Rama Khokha, Michael A. Dyer & David A. Largaespada. 2015. A Sleeping Beauty Forward Genetic Screen Identifies Genes Promoting Osteosarcoma Development and Metastasis. Nature Genetics. Jun; 47(6):615-24.